Risk Management Plans: Implementation of the New Pharmacovigilance Legislation in Mexico

被引：0

作者：

Duran, H. ^{[1
]}

Alatorre, R. ^{[2
]}

Lara, O. ^{[1
]}

机构：

[1] COFEPRIS, RMP Coordinat, Mexico City, DF, Mexico

[2] COFEPRIS, CEMAR, Mexico City, DF, Mexico

来源：

DRUG SAFETY | 2018年 / 41卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

ISoP18-144

引用

页码：1244 / 1245

页数：2

共 50 条

[21] New Pharmacovigilance Legislation: A Call to Arms to the Pharmacoepidemiology Community
Blackburn, Stella C. F.
Arlett, Peter R.
Evans, Stephen J.
Perez-Gutthann, Susana
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 339 - 339
[22] Getting to grips with the new European Union pharmacovigilance legislation
Waller, Patrick
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (05) : 544 - 549
[23] Comparing and Contrasting the Utility of Risk Management Plans and Periodic Safety Update Reports in Pharmacovigilance: A Regulatory Viewpoint
Storbeck, S. Drmanic
Semalulu, S.
Hashim, S.
Omara, E.
Vu, D.
DRUG SAFETY, 2012, 35 (10) : 891 - 892
[24] Wales plans new legislation on dangerous dogs
不详
VETERINARY RECORD, 2012, 171 (04) : 81 - 81
[25] Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?A Review of the New EU Legislation on Pharmacovigilance
John-Joseph Borg
George Aislaitner
Michal Pirozynski
Stephen Mifsud
Drug Safety, 2011, 34 : 187 - 197
[26] Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to? A Review of the New EU Legislation on Pharmacovigilance
Borg, John-Joseph
Aislaitner, George
Pirozynski, Michal
Mifsud, Stephen
DRUG SAFETY, 2011, 34 (03) : 187 - 197
[27] Patients' Knowledge of ADR in the Eve of the New European Pharmacovigilance Legislation
Lebanova, V.
Getov, I. N.
DRUG SAFETY, 2012, 35 (10) : 894 - 894
[28] Comment On: "EU's New Pharmacovigilance Legislation: Considerations for Biosimilars"
Borg, John Joseph
Serracino-Inglott, Anthony
Azzopardi, Lilian M.
Schneider, Christian K.
DRUG SAFETY, 2014, 37 (02) : 123 - 124
[29] Comment On: “EU’s New Pharmacovigilance Legislation: Considerations for Biosimilars”
John Joseph Borg
Anthony Serracino-Inglott
Lilian M. Azzopardi
Christian K. Schneider
Drug Safety, 2014, 37 : 123 - 124
[30] The New EU Legislation on Pharmacovigilance and Changing Models for Drug Development
Torbjörn Callréus
Drug Safety, 2011, 34 : 529 - 530

← 1 2 3 4 5 →